I think we are mixing the lawsuit, the FDA and politics here without any basis to do so. I don't share these same reservations about the FDA. Sure, they are bigger and probably slower to change versus the MHRA but i don't think they will be far behind in approving dcvax-l. Ultimately, we had a FDA mandated crossover option which lead to the use of an ECA. The FDA knew this could lead to the use of an ECA and they will Ultimately approve the results of a trial that showed unprecedented 5 year survival in nGBM and never before seen rGBM numbers.